Scarica l'app Stockscreener
35.99
5.51%
1.88
Precedente Chiudi:
$34.11
Aprire:
$36
Volume 24 ore:
1.99M
Relative Volume:
1.59
Capitalizzazione di mercato:
$2.76B
Reddito:
$13.17M
Utile/perdita netta:
$-199.06M
Rapporto P/E:
-13.14
EPS:
-2.74
Flusso di cassa netto:
$-156.53M
1 W Prestazione:
+4.62%
1M Prestazione:
+11.74%
6M Prestazione:
-8.89%
1 anno Prestazione:
-7.36%
Intervallo 1D:
$35.10
$37.60
Intervallo di 1 settimana:
$32.78
$37.60
Portata 52W:
$26.74
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Nome
Xenon Pharmaceuticals Inc
Settore
Industria
Telefono
(604) 484-3300
Indirizzo
200 - 3650 GILMORE WAY, BURNABY
Confronta XENE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
35.99 | 2.62B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-04 | Iniziato | Citigroup | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Iniziato | Goldman | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-10-19 | Iniziato | Raymond James | Outperform |
| 2022-08-29 | Iniziato | BofA Securities | Buy |
| 2022-07-21 | Iniziato | JP Morgan | Overweight |
| 2021-10-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-07-21 | Iniziato | Needham | Buy |
| 2020-06-01 | Ripresa | Jefferies | Buy |
| 2020-03-25 | Iniziato | Wedbush | Outperform |
| 2020-01-08 | Iniziato | William Blair | Outperform |
| 2019-09-20 | Iniziato | Guggenheim | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2017-03-13 | Iniziato | Jefferies | Buy |
| 2016-10-21 | Iniziato | Stifel | Buy |
| 2016-09-26 | Iniziato | Guggenheim | Buy |
| 2016-04-14 | Reiterato | Jefferies | Buy |
| 2015-10-30 | Ripresa | Jefferies | Buy |
| 2014-12-02 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
Xenon Pharmaceuticals: Azetukalner's 2026 Data Readouts and Multi-Indication Launch Potential - AInvest
Xenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With Phase 3 2026 Data Release - Seeking Alpha
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus - Nasdaq
Xenon Pharma Q2 2025 Earnings Preview - MSN
RBC Capital Adjusts Price Target on Xenon Pharmaceuticals to $55 From $57, Maintains Outperform Speculative Risk Rating - MarketScreener
Deutsche Bank Adjusts Xenon Pharmaceuticals Price Target to $57 From $60, Maintains Buy Rating - MarketScreener
Xenon targets NDA filing for azetukalner within 6 months of phase III readout while advancing late-stage neuropsychiatric programs - MSN
Xenon Pharmaceuticals Inc (XENE) Q2 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Xenon Pharmaceuticals Reports Q2 2025 Progress and Outlook - TipRanks
Xenon Pharmaceuticals Q2 2025 Earnings Call Transcript: Key Highlights - AInvest
Xenon Pharmaceuticals' Q2 2025: Navigating Contradictions in X-TOLE2 Enrollment, Dosing, and Safety Strategies - AInvest
Xenon Pharmaceuticals' Azetukalner: A High-Potential Biotech Catalyst Ahead of 2026 Topline Data - AInvest
Xenon Pharmaceuticals: Q2 Earnings Snapshot - San Francisco Chronicle
Transcript : Xenon Pharmaceuticals Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Xenon Completes Patient Recruitment for Phase 3 Study - TipRanks
Xenon Pharmaceuticals jumps after massive earnings beat - Investing.com India
Xenon Pharmaceuticals Inc. SEC 10-Q Report - TradingView
Xenon Pharmaceuticals Q2 Loss Widens, CFO Changes Announced - AInvest
Xenon Pharmaceuticals' Q2 2025 Earnings: A Catalyst for Neuroscience Innovation and Shareholder Value - AInvest
Xenon Pharmaceuticals Q2 Loss Widens - MarketScreener
Xenon Pharmaceuticals: A High-Conviction Play in Neurological Therapeutics with Azetukalner in Late-Stage Development - AInvest
Xenon Reports Second Quarter 2025 Financial Results & Business Update - GlobeNewswire
RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug - MSN
Signal strength of Xenon Pharmaceuticals Inc. stock in tech scannersFree Consistent Income Focused Trade List - Newser
Is Xenon Pharmaceuticals Inc. a candidate for recovery playDay Trading Setup Forecast with Trend Model - Newser
Institutional scanner results for Xenon Pharmaceuticals Inc.AI Intraday Market Movement Prediction Tool - Newser
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Acquired by Natixis Advisors LLC - Defense World
Should I buy Xenon Pharmaceuticals Inc. stock before earningsInvestment Timing Strategy with Market Filters - Newser
Xenon Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Published on: 2025-08-11 01:10:41 - Newser
Best data tools to analyze Xenon Pharmaceuticals Inc. stockStock Trading Session Highlights and Summary - Newser
Momentum divergence signals in Xenon Pharmaceuticals Inc. chartDaily Market Movers Screener with Filters - Newser
Quantitative breakdown of Xenon Pharmaceuticals Inc. recent moveFree AI Trading Suggestions With Accuracy Focus - Newser
Will a bounce in Xenon Pharmaceuticals Inc. offer an exitAI Risk Optimized Trade Forecast Planner - Newser
Measuring Xenon Pharmaceuticals Inc.’s beta against major indicesDaily Technical Chart Pattern Analysis Report - Newser
Xenon Pharmaceuticals Inc. stock trendline breakdownHigh Yield Signals with Entry Timing - Newser
Xenon Pharmaceuticals (XENE) to Release Earnings on Monday - Defense World
Is it too late to sell Xenon Pharmaceuticals Inc.Short Term Gain Strategy with AI Logic - Newser
Xenon Pharmaceuticals XENE 2025Q2 Earnings Preview Upside Potential on Innovative Product Launches - AInvest
Xenon Pharmaceuticals Inc expected to post a loss of 99 cents a shareEarnings Preview - TradingView
Fund Update: GEODE CAPITAL MANAGEMENT, LLC added 900,746 shares of XENON PHARMACEUTICALS ($XENE) to their portfolio - Quiver Quantitative
Zurcher Kantonalbank Zurich Cantonalbank Sells 318 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:XENE) - Defense World
Will Xenon Pharmaceuticals Inc. continue its uptrendMonthly Trade Result and Signal Summary - Newser
Xenon Pharmaceuticals Skyrockets 8.9%—What’s Fueling This Biotech Breakout? - AInvest
Xenon Pharmaceuticals to Announce Q2 2025 Financial Results - The Globe and Mail
Is Xenon Pharmaceuticals Inc. stock poised for growthFree Target Return Focused Trade Insights - Newser
Xenon Pharmaceuticals Announces Q2 2025 Financial Results and Business Update - AInvest
Why Xenon Pharmaceuticals’ Stock is Gaining Attention - TipRanks
Xenon Pharmaceuticals Inc. to Report Q2 2025 Financial Results and Business Update on August 11, 2025 - Quiver Quantitative
Xenon to Report Q2 2025 Financial Results on August 11, 2025 - GlobeNewswire
Xenon Pharmaceuticals Inc Azioni (XENE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):